Madison, WI, September 9, 2016 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that the company has received certification from British Standards Institution (BSI) Group America, Inc. that the company complies with the requirements of ISO 13485:2003 for an integrated Quality Management System across all functions of the business, from design and development to manufacturing and supply. The scope of the certificate includes the design, manufacture, and distribution of sterile wound dressings with medicinal substances.
“This is a crucially important step in bringing our first antimicrobial wound dressing product, MicroLyte AG, to global marketplace,” said Imbed’s President and CEO Ankit Agarwal. “Furthermore, I am very pleased that our small team has been able to achieve this certification in a relatively short period of time in a very capital efficient manner. ISO 13485 certification provides an important level of assurance to our customers and partners that Imbed can reliably provide high quality products.
About Imbed Biosciences, Inc.
Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation.
CEO, Imbed Biosciences Inc.